Antiamnesic effects of tofisopam against scopolamine-induced cognitive impairments in rats

Basit Öğe Kaydı
dc.authoridULUPINAR, EMEL/0000-0001-9684-5937
dc.authoridUcel, Umut Irfan/0000-0002-5470-0139
dc.contributor.authorUcel, Umut Irfan
dc.contributor.authorCan, Ozgur Devrim
dc.contributor.authorOzkay, Umide Demir
dc.contributor.authorUlupinar, Emel
dc.date.accessioned2024-10-04T18:48:16Z
dc.date.available2024-10-04T18:48:16Z
dc.date.issued2020
dc.departmentBayburt Üniversitesien_US
dc.description.abstractIn this study, we investigated the potential therapeutic effects of tofisopam, a 2,3-benzodiazepine derivative anxiolytic, on cognitive deficits in rats with scopolamine-induced amnesia. Cognitive performance of the rats was investigated by using the Morris water maze and passive avoidance tests. Changes in motor activity were assessed by using the activity cage and Rota-rod tests and then morphological changes in the hippocampus were assessed via immunohistochemical stainings. The results indicated that scopolamine impaired learning and memory parameters in rats. Worsened cognitive performance, neuronal loss, and decreased hippocampal synaptophysin, Ki-67, and glial fibrillary acidic protein density were observed. Tofisopam administration at a dose of 50 mg/kg for seven days improved the impaired cognitive performance, enhanced the attenuated synaptic transmission in the hippocampus, increased proliferation in subgranular zones, and improved the decrease in astrocytes in amnesic rats. These findings point out the anti-amnesic effects of tofisopam with concomitant improvements in the hippocampal synaptogenesis, neurogenesis, and glial plasticity, for the first time. Presented beneficial effects of tofisopam on cognitive dysfunctions may have a notable clinical value considering the fact that one of the most important side effects of 1,4-benzodiazepines, which are classical anxiolytic drugs, is amnesia. However, these preclinical results need to be confirmed with further clinical studies, first.en_US
dc.identifier.doi10.1016/j.pbb.2020.172858
dc.identifier.issn0091-3057
dc.identifier.pmid31981560en_US
dc.identifier.scopus2-s2.0-85078810740en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.pbb.2020.172858
dc.identifier.urihttp://hdl.handle.net/20.500.12403/2992
dc.identifier.volume190en_US
dc.identifier.wosWOS:000521117200001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofPharmacology Biochemistry and Behavioren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAmnesiaen_US
dc.subjectGFAPen_US
dc.subjectKi-67en_US
dc.subjectRaten_US
dc.subjectSynaptophysinen_US
dc.subjectTofisopamen_US
dc.titleAntiamnesic effects of tofisopam against scopolamine-induced cognitive impairments in ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu